Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Awakn Life Sciences Corp (OP: AWKNF )

0.2100 +0.0030 (+1.45%)
Streaming Delayed Price Updated: 11:26 AM EDT, Jun 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Awakn Life Sciences Corp

< Previous 1 2 3 4 Next >
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued 
Via Benzinga
Awakn's Q4 2023 And Annual Financials, +500% YoY Revenue Increase Following Network Expansion
The UK-based psychedelics biotech company Awakn Life Sciences Corp. (OTCQB: AWKNF) reported on its financial results and business highlights for the three and twelve months ended Jan. 31, 2023.   
Via Benzinga
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a... 
Via Benzinga
Severe Alcohol Use Disorder Patients Will Try Ketamine Therapy At Awakn's New Phase 3 Study
The research partnership between UK-based psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) and the University of Exeter for an upcoming 
Via Benzinga
EXCLUSIVE: MDMA Therapy Experts Debate Upcoming Approval And Psychedelic Market Opps
In the current psychedelics landscape, one of the most important topics is compound legality.  While it's possible that MDMA-assisted therapy will eventually be federally approved in the U.S., what... 
Via Benzinga
Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More
Revolutionizing Psychedelics: 2 Industry Leaders Team Up On Clinical-Grade MDMA Capsules 
Via Benzinga
Awakn's Psychedelics Medical Chief Steps Down, Shifts In Company's Stocks And Ownership
Awakn Life Sciences Corp. (OTCQB: AWKNF), the biotech company developing psychedelic therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD) shared its recent corporate... 
Via Benzinga
EXCLUSIVE: Ketamine Therapy Provider Nushama Co-Founder On Shifting From A Consciousness Of Blame Into A Space Of Responsibility
In light of the latest news regarding the DEA’s telehealth regulations and the 
Via Benzinga
Major Psychedelics VC & EFT Directors Will Share Valuable Insights At Upcoming Benzinga Event
The Benzinga Psychedelics Capital Conference (PCC) is rapidly becoming the place to be for all those interested or involved in the space. In addition to being the place where deals are done, you'll... 
Via Benzinga
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been... 
Via Benzinga
MDMA News: Exclusive Supply Deal With Awakn Life Sciences & Canadian Company Expands Psychedelics Production
PharmAla To Be Exclusive MDMA Supply Partner To Awakn Life Sciences Effective immediately, MDXX class molecules producer PharmAla Biotech Holdings Inc. will become the exclusive MDMA supplier to Awakn... 
Via Benzinga
Latest Psychedelics Deals: Optimi Supplies Australia, Awakn Partners Licensing In California
Optimi Health Enters Australian Medical Psychedelics Market Via Mind Medicine Australia 
Via Benzinga
Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More
Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and... 
Via Benzinga
Awakn's First Licensing Partnership Deal In Europe Involves Chain Of Portuguese Clinics
Awakn Life Sciences Corp. (OTCQB: AWKNF) has signed a licensing partnership agreement in Europe with a Portugal-based healthcare consortium currently operating in stealth mode.   
Via Benzinga
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and... 
Via Benzinga
Psychedelics For Alcohol Use Disorder: Awakn Opens European Clinic, FSD Launches R&D Program
Awakn Opens Fourth European Clinic, Norway Takes Center Stage 
Via Benzinga
Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More
Psychedelics Legislation: The Latest On Hawaii, Virginia, Missouri & More 
Via Benzinga
A New Way Of Delivering MDMA? Awakn And Tech Partner Are Set To Study Viability
Psychedelics biotech Awakn Life Sciences (OTCQB: AWKNF) has initiated a feasibility study of formulating and delivering MDMA through Catalent’s proprietary oral, 
Via Benzinga
Awakn's Ketamine Treatment For Alcohol Use Disorder Awarded UK's Fast-Track Status
Awakn Life Sciences Corp. (OTCQB: AWKNF), a biotech company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), has been granted an Innovation Passport for... 
Via Benzinga
Two New Studies On Classical Psychedelics: Grading Ketamine's Components, Tuning Down Psilocybin Dosing
Awakn’s First Study On Novel S-Ketamine Formulation To Assess Dissociative Effect 
Via Benzinga
What Happened With Psychedelics In The Last Year? 11 Key News Items, The Sector's Performance & Takeaways
What a year for psychedelics! 
Via Benzinga
6 Largest Psychedelic Drug Stocks Were -20% In December
The Psychedelic Drug Stocks Index, which tracks the six largest psychedelic stocks researching the treatment of mental illnesses based on the use of one or more psychedelic substances, continued to... 
Via Talk Markets
Largest Psychedelic Stocks DOWN 8% Last Week; DOWN 22% So Far This Month
Today's article highlights the performance of the munKNEE Psychedelic Drug Stocks Index which tracks the six (6) largest psychedelic stocks researching the treatment of mental illnesses based on the... 
Via Talk Markets
Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More
Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed. 
Via Benzinga
Awakn Unveils Q3 Results, Touts Revenue Growth, R&D Progress, Commercial Plans
Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) shared its financial results and business highlights for a three-month period that ended Oct. 31, 2022. Financials showed: 
Via Benzinga
UK Supports Psychedelic Research With Phase 3 Trial In Federal Health Sites
Awakn Life Sciences Corp. 
Via Benzinga
Major Psychedelic Drug Stocks DOWN 9% Last Week; Now Down 51% YTD
Today's article highlights the performance of the largest psychedelic stocks that research the treatment of a variety of mental illnesses based on the use of ten (10) different psychedelic substances. 
Via Talk Markets
Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project
Psychedelic Research & Fed Funding By The National Institute Of Mental Health The National Institute of Mental Health (NIMH) named the types of psychedelics studies to which it would grant funds and... 
Via Benzinga
Europe To Have Expanded Access To Psychedelic-Assisted Therapy With New Norway Clinic
Psychedelics biotech Awakn Life Sciences Corp. 
Via Benzinga
Psyched: Full-Dose & Microdosing LSD Studies, Research Scope For Fed Funding, Consumption Sites And More
LSD Research Ramps Up: Full-Dose & Microdosing For Alzheimer's Studies Led By Beckley Foundation Coming Soon 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.